

29 May 2023

ASX Announcement

ADALTA TO PRESENT AT JUNE 1 VIRTUAL INVESTOR SUMMIT

MELBOURNE Australia, 29 May 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, advises that its CEO and Managing Director, Dr Tim Oldham, would be presenting at the Virtual Investor Summit on 1 June, hosted by Investor Summit Group.

During his presentation, Dr Oldham will describe the products that AdAlta is developing to treat challenging diseases such as fibrosis and cancer, all underpinned by the company's proprietary i-body technology. A specific focus of the presentation will be the opportunities to return lead program AD-214 to clinical trials earlier than expected and the licensing transaction opportunities across the portfolio being enabled by the current capital raising. The presentation will be livestreamed, and a recorded copy made available on AdAlta's website.

Event: June 1st Investor Summit
Presentation: June 1, 2023 at 12:00 p.m. EST
Location: https://us06web.zoom.us/webinar/register/WN_T_KYXY8PSfuWYQvI018NUQ

- One-on-one meetings will be available for qualified, registered investors
- The conference is completely complimentary to qualified investors. Please register at [Complimentary Investor Registration](#)

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
May 2023

Shareholders: please update your communication preferences

We encourage shareholders to update their share registry preferences to receive all communications electronically. Doing so helps us communicate with you in a time-efficient manner on important matters, while minimising our mail costs and environmental impact.

Simply [click here](#) or scan the QR code and follow the instructions.

Not a shareholder, but want to keep across our progress? [Click here](#) to subscribe to our updates using the Stay in Touch form.



Notes to Editors

About the Investor Summit

[The Investor Summit](#) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Investor Summit will take place virtually, featuring micro-cap companies and institutional, family office, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Technology, Financial, Healthcare, Industrials, Materials, Real Estate. Contact: emily@investorsummitgroup.com

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in pre-clinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au